指南与共识乳腺癌放疗放疗物理与技术

单中心应用ASTRO共识指南术前筛选导管原位癌患者接受术中放疗的经验

A Single-Institution Experience in the Preoperative Selection of DCIS Patients for IORT using the ASTRO Consensus Guidelines.
指南 / 共识 · Adv Radiat Oncol · 2018-11-20

本研究基于单中心前瞻性登记数据库,分析2013年9月至2017年2月收治的60例纯导管原位癌患者(61个病灶),按ASTRO共识指南术前分为适合、谨慎、不适合三组接受术中放疗。术前35%适合、59%谨慎、6%不适合;最终病理使16%患者分组改变,不适合者中66%接受补充全乳放疗;中位随访2.2年,适合组2例、谨慎组1例同侧乳腺肿瘤复发,不适合组无复发。结论认为需进一步研究优化术中放疗单用候选者的筛选。

要点

  • 术前按ASTRO共识指南分组:适合35%、谨慎59%、不适合6%。
  • 最终病理使16%患者分组改变,其中3%为隐匿高级别病变、13%为切缘近/阳性。
  • 不适合者中66%接受补充全乳放疗,中位随访2.2年不适合组无同侧乳腺肿瘤复发。

核心结论

  • 需要进一步研究以优化可单独接受术中放疗的导管原位癌患者的筛选。
  • 不适合患者对补充治疗的高接受率带来了极好结局。
  • 在传统临床和病理因素之外使用生物标志物可能有助于更好地筛选术中放疗患者。

研究设计与样本

  • 单中心前瞻性登记数据库研究,纳入2013年9月至2017年2月经活检证实的纯导管原位癌患者,使用Zeiss Intrabeam®设备行术中放疗。
  • 依据可获得的术前临床病理信息按ASTRO共识指南将患者分为适合、谨慎或不适合术中放疗。
  • 共治疗60例患者的61个导管原位癌病灶。

主要发现

  • 术前21例(35%)为适合、36例(59%)为谨慎、4例(6%)因病灶大小不适合但拒绝全乳放疗。
  • 最终病理诊断使10例(16%)患者共识指南分组改变,其中2例(3%)为隐匿高级别病变、8例(13%)为切缘近/阳性。
  • 最终共12例被认为不适合,其中8例(66%)在术中放疗后接受补充全乳放疗。
  • 中位随访2.2年,同侧乳腺肿瘤复发见于2例适合患者、1例谨慎患者,不适合患者中无复发。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intraoperative radiation therapy (IORT) as a form of accelerated partial breast irradiation (APBI) is controversial given the limited evidence to support its efficacy. However, it remains an attractive option for low-risk patients with ductal carcinoma in situ (DCIS), who derive a small absolute benefit in local control with standard whole breast irradiation (WBI). We examine how the American Society for Therapeutic Radiation Oncology (ASTRO) APBI consensus guidelines (CG) may be applied to the preoperative selection of patients with DCIS for IORT and determine treatment outcomes by CG group. METHODS AND MATERIALS: We identified patients with biopsy-proven pure DCIS enrolled in an institutional prospective registry IORT database using the Zeiss Intrabeam® device between September 2013 and February 2017. Based on available preoperative clinicopathologic information, patients were deemed suitable, cautionary, or unsuitable for IORT according to the ASTRO CG. Change in CG group based on final pathologic diagnosis was determined, and additional therapy was recommended for unsuitable patients. Outcome in terms of ipsilateral breast tumor recurrence was determined. RESULTS: A total of 61 DCIS lesions in 60 patients were treated with IORT. Preoperatively, 21 patients (35%) were suitable and 36 (59%) were cautionary. Four (6%) were unsuitable because of lesion size but declined WBI. Final pathologic diagnosis changed the CG grouping of 10 patients (16%) because of either occult high-grade disease in 2 (3%) or close/positive margins in 8 (13%). Ultimately 12 patients total were considered unsuitable, of whom 8 (66%) accepted additional WBI after IORT. At a median follow-up of 2.2 years, ipsilateral breast tumor recurrence was identified among 2 suitable, 1 cautionary, and no unsuitable patients. CONCLUSION: Further investigation is necessary to refine selection of patients with DCIS who may be optimally treated with IORT alone. High acceptance of additional therapy among unsuitable patients resulted in excellent outcomes. The use of biomarkers in addition to traditional clinical and pathologic factors may help to better select patients for IORT.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chin C, Hirji S, Onishi M, et al. A Single-Institution Experience in the Preoperative Selection of DCIS Patients for IORT using the ASTRO Consensus Guidelines. Adv Radiat Oncol. 2018. PMID: 31011670. doi:10.1016/j.adro.2018.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。